Finance

Lists
PTKFY:OTCMKTS
PT Kalbe Farma Unsponsored Indonesia ADR
US$8,50
0,00%
(0,00) 1D
12 ຕ.ລ., 10 ໂມງ 22 ນາທີ 09 ວິນາທີ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PTKFY...
Mkt. cap
31,60ລລ
Avg. vol.
1,94 ພັນ
Volume
1,43 ພັນ
52-wk high
US$16,36
52-wk low
US$7,63
Beta
0,09
Shares outstanding
234,07 ລ້ານ
No. of employees
13 ພັນ
Mkt. cap
31,60ລລ
Avg. vol.
1,94 ພັນ
Volume
1,43 ພັນ
52-wk high
US$16,36
52-wk low
US$7,63
Beta
0,09
Shares outstanding
234,07 ລ້ານ
No. of employees
13 ພັນ
News stories
From web sources and news partners
ad-hoc-news.de
ad-hoc-news.de
·
14 ຊົ່ວໂມງກ່ອນ
Buyback plans and results shaped Kalbe Farma stock review
ad-hoc-news.de
ad-hoc-news.de
·
1 ມື້ກ່ອນ
Kalbe Farma stock falls 14.56 percent to IDR 675.00
Profile
PT Kalbe Farma Tbk, or simply known as Kalbe, is an Indonesian pharmaceutical, healthcare and nutrition company established in 1966. The company has expanded by strategic acquisitions of pharmaceutical companies, becoming an integrated consumer health and nutrition enterprise. The Kalbe Group has brands in the prescription drugs, OTC drugs, energy drink and nutrition products, with a distribution arm that reaches over one million outlets. Notably, the company produces misoprostol, a drug which is used to treat stomach ulcers but is also widely used in Indonesia as an illegal abortifacient. Company brands in healthcare and pharmaceutical segments include Promag, Mixagrip, Woods, Komix, Diabetasol, Prenagen, Extra Joss and Fitbar. Kalbe is the largest publicly listed pharmaceutical company in Southeast Asia with around US$5 billion in market capitalization and revenues of over Rp 15 trillion. The name "Kalbe" is a syllabic abbreviation of its founder's name: Khouw Lip Boen. Wikipedia
About PT Kalbe Farma Unsponsored Indonesia ADR
CEO-
Employees12,8 ພັນ
Founded10 ກ.ຍ. 1966
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in IDR
Loading Previous Earnings...
Revenue
Net income
All values in IDR
ກ.ຍ. 2025
ທ.ວ. 2025
ມ.ນ. 2026
ມິ.ຖ. 2026
Revenue
8,91 ລ້ານລ້ານ
9,34 ລ້ານລ້ານ
9,68 ລ້ານລ້ານ
9,80 ລ້ານລ້ານ
Cost of goods sold
5,46 ລ້ານລ້ານ
5,92 ລ້ານລ້ານ
6,02 ລ້ານລ້ານ
6,25 ລ້ານລ້ານ
Cost of revenue
5,46 ລ້ານລ້ານ
5,92 ລ້ານລ້ານ
6,02 ລ້ານລ້ານ
6,25 ລ້ານລ້ານ
Research and development expenses
98,31 ຕື້
160,88 ຕື້
113,14 ຕື້
122,60 ຕື້
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2,51 ລ້ານລ້ານ
1,95 ລ້ານລ້ານ
2,23 ລ້ານລ້ານ
2,27 ລ້ານລ້ານ
Operating expense
2,60 ລ້ານລ້ານ
2,14 ລ້ານລ້ານ
2,33 ລ້ານລ້ານ
2,39 ລ້ານລ້ານ
Total operating expenses
8,06 ລ້ານລ້ານ
8,05 ລ້ານລ້ານ
8,36 ລ້ານລ້ານ
8,64 ລ້ານລ້ານ
Operating income
851,77 ຕື້
1,28 ລ້ານລ້ານ
1,32 ລ້ານລ້ານ
1,16 ລ້ານລ້ານ
Other non operating income
-3,78 ຕື້
-4,17 ຕື້
-3,63 ຕື້
-3,74 ຕື້
EBT including unusual items
877,87 ຕື້
1,30 ລ້ານລ້ານ
1,36 ລ້ານລ້ານ
1,19 ລ້ານລ້ານ
EBT excluding unusual items
888,55 ຕື້
1,30 ລ້ານລ້ານ
1,36 ລ້ານລ້ານ
1,18 ລ້ານລ້ານ
Income tax expense
211,19 ຕື້
252,81 ຕື້
303,84 ຕື້
271,57 ຕື້
Effective tax rate
24,06%
19,41%
22,40%
22,80%
Other operating expenses
-7,23 ຕື້
31,35 ຕື້
-10,02 ຕື້
2,13 ຕື້
Net income
656,41 ຕື້
1,03 ລ້ານລ້ານ
1,03 ລ້ານລ້ານ
890,54 ຕື້
Net profit margin
7,37%
11,07%
10,63%
9,09%
Earnings per share
14,44
22,72
22,74
19,68
Interest and investment income
41,31 ຕື້
40,43 ຕື້
32,07 ຕື້
43,61 ຕື້
Interest expense
-9,69 ຕື້
-5,77 ຕື້
-4,61 ຕື້
-6,78 ຕື້
Net interest expenses
31,62 ຕື້
34,66 ຕື້
27,46 ຕື້
36,83 ຕື້
Depreciation and amortization charges
-
-
-
-
EBITDA
1,05 ລ້ານລ້ານ
1,45 ລ້ານລ້ານ
1,51 ລ້ານລ້ານ
1,20 ລ້ານລ້ານ
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
ແອັບຂອງ Google